What values are normal in healthy controls for endurance and force? Are these values the same for men and female? What is the effect of age to these normal values? What are endurance and force for patients with myasthenia gravis? Are there specific…
ID
Source
Brief title
Condition
- Neuromuscular disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
QMG Score and QMA Score: normal values for different diseases, adapted for age
and gender.
Secondary outcome
QMG/QMA ratio: differences between helathy controls and patients? difference
between MG and other neuromuscular diseases?
Background summary
Myasthenia Gravis is a disease characterized by muscle weakness and fatigue of
voluntary muscles. Progressive weakness during sustained exercise is considered
characteristic for MG and its presence is used as a diagnostic tool. Proper
muscle diseases, like IBM or myotonic dystrophy, are characterized by weakness
but not by a lack of endurance, or so textbooks and experts say.
These teste, measuring muscle force and endurability, are scarcely validated.
Study objective
What values are normal in healthy controls for endurance and force? Are these
values the same for men and female? What is the effect of age to these normal
values?
What are endurance and force for patients with myasthenia gravis? Are there
specific endurance and force patterns for patients with other forms of muscle
weakness, like myotonic dystrophy, inclusion body myositis or other
neurological diseases?
Study design
The research protocol consists of two questionnaires (patient characteristics
and ACTIVLIM) and two tests (QMG score and QMA score).
The first questionnaire contains questions regarding descriptive patient
characteristics and additional factors that may influence muscle strength or
endurance(addendum 4). The second questionnaire, ACTIVLIM, (addendum 5)
comprises of 22 short questions.
The QMG Score (addendum 1) involves a standardized test protocol (addendum 2).
The items are recorded in the same order for all patients. The endurance tests
in the present version of the QMG Score now have a predefined maximum score,
above which endur-ance is considered normal. To test this assumption, the
period of time during which peo-ple are asked to perform the task will be
doubled (for example, subjects will be asked to hold their leg stretched for
200 instead of 100 seconds). A hand-held dynamometer will be used for patient*s
grip strength.
The QMA Score tests the maximum force of patients of biceps, triceps,
quadriceps femoris and hamstrings muscles of both sides.
Study burden and risks
40 minutes, once. In MG patients short-term withdrawal of pyridostigmin just
prior to testing is not harmful, although it might be uncomfortable.
Albinusdreef 2
2333 ZA
Nederland
Albinusdreef 2
2333 ZA
Nederland
Listed location countries
Age
Inclusion criteria
myasthenia gravis
neurological disease, that affects muscle strength
age over 12 years old
Exclusion criteria
non-neurological disorder that will affect muscle strength testing (eg rheumatoid arthritis)
combination of different disorders with effect on muscle strength
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL20326.058.07 |